Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2005-12-20
2005-12-20
Spector, Lorraine (Department: 1646)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C530S388220, C530S350000, C530S389100, C530S387100, C530S387300
Reexamination Certificate
active
06977240
ABSTRACT:
The present invention relates to the discovery, identification and characterization of nucleotides that encode Ob receptor (ObR), a receptor protein that participates in mammalian body weight regulation. The invention encompasses obR nucleotides, host cell expression systems, ObR proteins, fusion proteins, polypeptides and peptides, antibodies to the receptor, transgenic animals that express an obR transgene, or recombinant knock-out animals that do not express the ObR, antagonists and agonists of the receptor, and other compounds that modulate obR gene expression or ObR activity that can be used for diagnosis, drug screening, clinical trial monitoring, and/or the treatment of body weight disorders, including but not limited to obesity, cachexia and anorexia.
REFERENCES:
patent: 5643748 (1997-07-01), Snodgrass et al.
patent: 5935810 (1999-08-01), Friedman et al.
patent: 5965521 (1999-10-01), Stephens et al.
patent: WO 93/07294 (1993-04-01), None
patent: WO 96/08510 (1996-03-01), None
patent: WO 97/12037 (1997-04-01), None
patent: WO 97/25424 (1997-07-01), None
patent: WO 97/25425 (1997-07-01), None
patent: WO 97/25425 (1997-07-01), None
Kovacina et al., “Characterization of the Endogenous Insulin Receptor-related Receptor in Neuroblastomas”, The Journal of Biological Chemistry, Vo. 270, No. 4, pp. 1881-1887, 1995.
Fernandez-Pol, “Epidermal Growth Factor Receptor of A431 Cells”. The Journal of Biological Chemistry, Vo. 260, No. 8, pp. 5003-5011, 1985.
Tepper et al., “Role for ceramide as an endogenous mediator of Fas-induced cytotoxicity”, Proc. Natl. Acad. Sce. USA, vol. 92, pp. 8443-8447, Aug. 1995.
Zeigler et al., “Cellular and Molecular Characterization of the Role of the FLK-2/FLT-3 Receptor Tyrosine Kinase in Hematopoietic Stem Cells”, Blood, Vo. 84, No. 8, pp. 2422-2430, Oct. 15, 1994.
Pelleymounter et al., Science, 269:540-543, 1995.
Halaas et al., Science, 269:543-546, 1995.
Campfield et al., Science, 269:546-549, 1995.
Friedman et al., Cell, 69:217-220, 1992.
Tartaglia et al., Cell, 83:1263-1271, Dec. 29, 1995.
Kovacina et al., “Characterization of the Endogenous Insulin Receptor-related Receptor in Neuroblastomas”, The Journal of Biological Chemistry, Vo. 270, No. 4, pp. 1881-1887, 1995.
Fernandez-Pol, “Epidermal Growth Factor Receptor of A431 Cells”. The Journal of Biological Chemistry, Vo. 260, No. 8, pp. 5003-5011, 1985.
Tepper et al., “Role for ceramide as an endogenous mediator of Fas-induced cytotoxicity”. Proc. Natl. Acad. Sce. USA, vol. 92, pp. 8443-8447, Aug. 1995.
Annotation for T73849 from Washington Merck EST Project, Mar. 2, 1995.
Annotation for T74249 from Washington Merck EST Project, Mar. 2, 1995.
Bray, G. A., “1989 McCollum Award Lecture. Genetic and hypothalamic mechanisms for obesity—finding the needle in the haystack”, Am. J. Clin. Nutr., 50:891-902, 1989.
Bray et al., “Hypothalamic and Genetic Obesity in Experimental animals: an Autonomic and Endocrine Hypothesis”, Physiological Reviews, 59:719-809, 1979.
Campfield et al., “Recombinant Mouse OB Protein: Evidence for a Peripheral Signal Linking Adiposity and Central Neural Networks”, Science, 269:546-549, 1995.
Chen et al., “Evidence that the Diabetes Gene Encodes the Leptin Receptor: Identification of a Mutation in the Leptin Receptor Gene in db/db Mice”, Cell, 84:491-495, 1996.
Chua et al., “Phenotypes of Mouse diabetes and Rat fatty due to Mutations in the OB (Leptin) Receptor”, Science, 271:877-1024, 1996.
Coiffi et al., “Novel B219/OB Receptor Isoforms: Possible role of Leptin in Hematopoiesis and Reproduction”, Nature Medicine, 2(5):585-589, 1996.
Coleman, D. L., “Effects of Parabiosis of Obese with Diabetes and Normal Mice”, Diabetologia, 9:294-298, 1973.
Coleman, D. L., “Obese and Diabetes: Two Mutant Genes Causing Diabetes-Obesity Syndrome in Mice”, Diabetologia, 14:141-148, 1978.
Considine et al., “Evidence Against Either a Premature Stop Codon or the Absence of Obese Gene mRNA in Human Obesity”, J. Clin. Invest., 95:2986-2988, 1995.
Considine et al., “The Hypothalamic Leptin Receptor in Humans: Identification of Incidential Sequence . . . ”, Diabetes, 19:992-994, 1996.
Friedman et al., “Tackling a Weighty Problem”, Cell, 69:217-220, 1992.
Gura, T., “Antisense Has Growing Pains”, Science, 270:575-557, 1995.
Halaas et al., “Weight-Reducing Effects of the Plasma Protein Encoded by the obese Gene”, Science, 269:543-546, 1995.
Hamilton et al., “Increased obese mRNA expression in omental fat cells from massively obese humans”, Nature Med., 1:(9)953-956, 1995.
Hollenbaugh et al., “Current Protocols in Immunology”, New York, pp. 10.19.1-10.19.11, 1992.
Hummel et al., “Diabetes, a New Mutation in the Mouse”, Science, 153:1127-1128, 1966.
James, W., “Towards Gene-Inhibition Therapy: A Review of Progress and Prospects in the Field of Antiviral Antisense Nucleic . . . ”, Antiviral Chem. & Chemo., 2(4):191-214, 1991.
Ledley, F., “Nonviral Gene Therapy: the Promise of Genes as Pharmaceutical Products”, Human Gene Therapy, 6:1120-1144, 1995.
Lee et al., “Abnormal splicing of the Leptin receptor in diabetic mice”, Nature, 379:632-635, 1996.
Lonnqvist et al., “Overexpression of the obese (ob) gene in adipose tissue of human obese subjects”, Nature Med., 1:950-953, 1995.
Madej et al., “Threading Analysis Suggests that the Obese Gene Product may be a Helical Cytokine”, FEBS Letters, 373:13-18, 1995.
Maffei et al., “Leptin levels in human and rodent: Measurements of plasma leptin and ob RNA in obese and weight-reudced subjects”, Nature Med., 1:1155-1161, 1995.
Miller et al., “Gene Transfer and Antisense Nucleic Acid Techniques”, Parasitology Today, 10(3):92-97, 1994.
Mulligan, R., “The Basic Science of Gene Therapy”, Science, 260:926-931, 1993.
Murakami et al., “Cloning of RAT Obese cDNA and its Expression in Obese Rats”, Biochem. & Biophys. Res. Com., 209(3):944-952, 1995.
Nishina et al., “Atherosclerosis in Genetically Obese Nice: The Mutants Obese, Diabetes, Fat, Tubby, and Lethal Yellow”, Metabolism, 43:(5)554-558, 1994.
Pelleymounter et al., “Effects of the obese Gene Product on Body Weight Regulation in ob/ob Mice”, Science, 269:540-543, 1995.
Redemann et al., “Anti-Oncogenic Activity of Signalling-Defective Epidermal Growth Factor Receptor Mutants”, Mol. & Cell. Biol., 12(2):491-498, 1992.
Sealfon, S., Receptor Molecular Biology: Methods in Neuroscience, San Diego: Academic Press, 25:278-301 and 470-509, 1995.
Seed et al., “Developments in Expression Cloning”, Current Opinion in Biotech., 6:567-573, 1995.
Stein et al., “Antisense Oligonucleotides as Therapeutic Agents—Is the Bullet Really Magic?”, Science, 261:1004-1012, 1993.
Stephens et al., “The role of neuropeptide Y in the antiobesity action of the gene product”, Nature, 377:530-532, 1995.
Stull et al., “Antigene, Ribozyme and Aptame Nucleic Acid Drugs: Progress and Prospects”, Pharm. Res., 12:465-483, 1995.
Tartaglia et al., “Identification and Expression Cloning of a Leptin Receptor, OB-R”, Cell, 83:1263-1271, 1995.
Wang et al., “A Novel Leptin Receptor Isoform in Rat”, FEBS, 392:87-90, 1996.
Wu-Pong, S., “Oligonucleotides: Opportunities for Drug therapy and Research”, Pharm. Tech., pp. 102-114, 1994.
Zhang et al., “Positional cloning of the mouse obese gene and its human homologue”, Nature, 372:425-431, 1994.
Maffei, M. et al., Proc. Natl. Acad. Sci USA 92 :6957-6960 (1995).
Culpepper Janice A.
Tartaglia Louis A.
Tepper Robert I.
White David W.
Millenium Pharmaceuticals, Inc.
Millennium Pharmaceuticals Inc.
O'Hara Elieen B.
Spector Lorraine
LandOfFree
Methods of using the OB receptor antibodies to treat... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods of using the OB receptor antibodies to treat..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of using the OB receptor antibodies to treat... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3505956